Viridian Therapeutics Aktie

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.» Mehr auf zacks.com

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 achieved significant efficacy in the Thrive trial, meeting all primary and secondary endpoints with strong proptosis and diplopia resolution rates, and was well-tolerated. Financially, Viridian has a market cap of $1.87bn and a cash runway of 9–10 quarters, with a potential annual revenue of $8bn if successful.» Mehr auf seekingalpha.com

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the paragraphs below.» Mehr auf seekingalpha.com